Zydus Lifesciences gets in-principle approval from WHO for ZyVac TCV, shares up 2%

Zydus Lifesciences Ltd

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Zydus Lifesciences rose over 2 percent after the company said that it has received in principle approval from the World Health Organization (WHO) for its vaccine, ZyVac TCV. This makes ZyVac TCV eligible for purchase by United Nations (UN) procurement agencies.

At 12.10 PM, shares of the company traded almost 2 percent higher at Rs 1,006. On a year-to-date basis the stock has gained over 44 percent, outperforming the Nifty 50 index which gained 13 percent during the same period.

ZyVac TCV is an indigenously developed typhoid vaccine, manufactured at the Zydus Biotech Park in Ahmedabad. It is designed for active immunization against Salmonella typhi infection in individuals aged 6 months to 65 years.

Follow our live blog for all the market action

The WHO's prequalification allows ZyVac TCV to be included in UN agencies which annually purchase over 150 million doses of the vaccine to combat typhoid in regions such as India, Africa, and Southeast Asia.

According to GAVI (2022), India accounts for 75 percent of the global incidence and mortality related to typhoid fever, with an estimated 11 to 21 million cases of febrile illness and 117,000 to 161,000 deaths attributed to the disease each year. Data reviewed by the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) indicates that children under five years of age are particularly vulnerable, accounting for 27 percent of all typhoid cases.

Zydus Lifesciences is a global life sciences company that focuses on discovering, developing, manufacturing, and marketing a wide range of healthcare therapies.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.